Safety of oral resin for treatment of hyperkalemia in Chinese patients with renal insufficiency

Trial Identifier: D9483R00002
Sponsor: AstraZeneca
NCTID:: NCT05462119
Start Date: August 2022
Primary Completion Date: December 2023
Study Completion Date: December 2023

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
China Beijing, China
China Dalian, China
China Dongyang, China
China Hangzhou, China
China Hefei, China
China Jinan, China
China Kaifeng, China
China Ningbo, China
China Qingdao, China
China Shijiazhuang, China
China Tianjin, China
China Xuzhou, China
China Yangzhou, China
China Zhangjiagang, China
China Zhengzhou, China
China, Beijing Beijing, China